research Targeting mTORC1 May Provide Selectivity for Inhibiting Proliferation of Hair Follicle Stem/Progenitor Cells During Tumor Promotion
Blocking mTORC1 may help prevent skin cancer by stopping the growth of certain skin stem cells.
Search
for
Sort by
Research
420-450 / 777 results
research Rash from EGFR Inhibitors: Opportunities and Challenges for Palliation
EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
research Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
EGFR-TKIs can cause significant skin, nail, and organ side effects.
research Drugs and Hair Loss: Mechanisms and Clinical Implications
Some medications can cause hair loss, but stopping the drug usually leads to recovery within 3 months.
research Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-Small Cell Lung Cancer
A cancer patient's eyelashes grew excessively without other common side effects after taking the cancer drug erlotinib.
research Eyelash Trichomegaly: A Rare Presenting Feature of Systemic Lupus Erythematosus
A girl with lupus had unusually long and thick eyelashes, a rare symptom of her condition.
research Treatment of Acne with Intermittent Isotretinoin: Cohort Study
Intermittent isotretinoin can cause various skin, hair, and nail changes.
research Mitigation of Epidermal Growth Factor Receptor Inhibitor-Induced Side Effects Utilizing Melanin and Vascular-Specific Lasers: A Case Report Series
Lasers can help reduce skin side effects from cancer treatment.
research When Bugs and Drugs Conspire: Driving Acneiform Skin Toxicity
Certain cancer drugs interact with skin bacteria to cause acne-like rashes.
research The Relevance of Collagen XVII Expression in Epidermal Differentiation and Proliferation
Collagen XVII is crucial for skin cell growth and nail health.
research PRIDE Syndrome Associated With Panitumumab Treatment – Case Report and Literature Review
A man's severe skin reaction from cancer treatment improved with early diagnosis and proper medication.
research Topical Application of Aprepitant Inhibits Erlotinib-Induced Facial Dermatitis and Hair Loss
Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
research Classification and Management of Skin, Hair, Nail, and Mucosal Side Effects of Epidermal Growth Factor Receptor Inhibitors
EGFR inhibitors often cause skin problems and other side effects, but these are usually reversible and can be managed to keep patients comfortable.
research Arrow Sign: A Rapid Microscopic Diagnosis of Hair Change Associated with Epidermal Growth Factor Receptor Inhibitors
A new method quickly detects hair changes from EGFR inhibitors using a microscope.
research Dermatologic Adverse Events Associated With Afatinib: An Oral ErbB Family Blocker
Afatinib often causes skin problems that need proactive management.
research Cutaneous Adverse Events to Systemic Antineoplastic Therapies: A Retrospective Study in a Public Oncologic Hospital
Skin side effects from cancer treatments can lead to changes in therapy and are common, with nail changes being the most frequent.
research The PRIDE Syndrome: Dermatological Side Effects of EGFR Inhibitors
PRIDE syndrome includes skin and hair issues from cancer treatment with EGFR inhibitors.
research Epidermal Growth Factor Receptor Inhibitor-Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent?
You might not need to stop cancer treatment if you get a rare skin reaction from EGFR inhibitors, as skin treatments can help manage it.
research Folliculitis Decalvans-Like Alopecia During EGFR Inhibitors Treatment for Lung Cancer: A Case Series of 6 Patients
Some lung cancer patients treated with EGFR inhibitors may develop a hair loss condition similar to folliculitis decalvans.
research Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor
Cetuximab often causes skin problems, but they can be managed without stopping treatment.
research Y27632 Promotes Proliferation via EGFR Signaling in a Newly Isolated and Characterized Human Primary Sebocyte Cell Line
Y27632 increases cell growth through EGFR signaling, not ROCK1/2.
research Trichomegaly of the Eyelashes Following Treatment with Cetuximab
Cetuximab can cause excessive eyelash growth.
research An Overview of Management of Drug-Induced Hair and Nail Disorders
Cooling the scalp may prevent hair loss from chemotherapy, hair often grows back after treatment, and nail issues usually improve after stopping the drug.
research Salt-Losing Tubulopathy and Chronic Dermatitis
Genetic testing for EGFR mutations is crucial in similar cases.
research Semiology of Skin Toxicity Associated with Epidermal Growth Factor Receptor Inhibitors
Skin problems like acne, dry skin, and nail and hair changes are common in patients taking EGFR inhibitors.
research Mario Lacouture: How Do I Treat a Patient with Dermatologic Toxicities to EGFR Inhibitors?
Dr. Mario Lacouture recommends preventive and specific treatments for skin side effects caused by EGFR inhibitors to improve patients' quality of life.
research EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.
research Fatal Toxic Epidermal Necrolysis Associated With Cetuximab in a Patient With Colon Cancer
A cancer patient died from a severe skin reaction after taking the drug cetuximab.
research Management of Dermatologic Toxicities
Doctors should actively prevent and treat skin side effects in cancer patients to keep them on the best medication and reduce discomfort.
research Successful Treatment of Epidermal Growth Factor Receptor Inhibitor-Induced Alopecia with Doxycycline
Doxycycline can effectively treat hair loss caused by EGFR inhibitors.